Acrylonitrile CASRN 107-13-1 | IRIS

IRIS

Acrylonitrile

CASRN 107-13-1 | DTXSID5020029

IRIS Summary (PDF) (23 pp, 162 K)
Status: Development of the acrylonitrile (re)assessment has been discontinued .

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (23 pp, 162 K) Last Updated:
Not assessed under the IRIS Program.

Reference Concentration for Inhalation Exposure (RfC) (PDF) (23 pp, 162 K) Last Updated: 11/01/1991

System	RfC (mg/m³)	Basis	PoD	Composite UF	Confidence
Respiratory	2 x 10 ^-3	Degeneration and inflammation of nasal respiratory epithelium; hyperplasia of mucous secreting cells	LOAEL (HEC): 1.9 mg/m³	1000	Medium

Cancer Assessment

Weight of Evidence for Cancer (PDF) (23 pp, 162 K) Last Updated: 09/30/1987

WOE Characterization	Framework for WOE Characterization
B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans)	Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986)

Basis:

The observation of a statistically significant increase in incidence of lung cancer in exposed workers and observation of tumors, generally astrocytomas in the brain, in studies in two rat strains exposed by various routes (drinking water, gavage, and inhalation) forms the basis for this classification.
This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (23 pp, 162 K)

Oral Slope Factor: 5.4 x 10^-1 per mg/kg-day
Drinking Water Unit Risk: 1.5 x 10^-5 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Nervous, Other, Gastrointestinal
Tumor type(s): Brain and spinal cord astrocytomas, Zymbal gland carcinomas and stomach papillomas/ carcinomas (Biodynamics, 1980a,b Quast et al., 1980a)

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (23 pp, 162 K)

Inhalation Unit Risk: 6.8 x 10^-5 per µg/m³
Extrapolation Method: Average relative risk
Tumor site(s): Respiratory
Tumor type(s): Respiratory cancer (O'Berg, 1980)